Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831471 | 0.92 | SQOR (0.46) | IKBKBAKT1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL29831380 | 0.90 | SQOR (0.44) | IKBKBLRRK2AKT1CYP11B1CYP11B2 | |
| SCHEMBL23163741 | 0.87 | CNR1 (0.42) | SGMS2SQOR | |
| SCHEMBL29831391 | 0.87 | SGMS2 (0.40) | LRRK2AKT1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL23164289 | 0.81 | PPIA (0.43) | LRRK2SGMS2 | |
| SCHEMBL23163731 | 0.81 | IKBKE (0.41) | IKBKBAKT1SGMS2 | |
| SCHEMBL23163728 | 0.81 | CTSC (0.44) | CYP11B1CYP11B2SGMS2GSK3AGSK3B | |
| SCHEMBL23164077 | 0.81 | PARP10 (0.49) | SGMS2 | |
| SCHEMBL29831611 | 0.81 | AKT1 (0.48) | IKBKBLRRK2AKT1F2SGMS2 | |
| SCHEMBL23163750 | 0.80 | LMNA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-07-08 | — | — | US | disclosed |
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FD (FR) | 2022-11-17 | — | — | US | disclosed |
| EP-4037770-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363643-A1 | NOVEL PYRIDIN-2(1H)ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF PAIN | P2RX3, OPRL1, P2RX6 | IKBKB 1928/4885LRRK2 2372/4885AKT1 4107/4885 |
| US-12351556-B2 | Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain | P2RX3, P2RX6, P2RX4 | IKBKB 1609/4885LRRK2 2582/4885AKT1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.